Facilitating pharma's future
BioCentriq, New Jersey’s newest CDMO, is designed to help usher in the next era of cell and gene therapy
Launching a state-of-the-art facility focused on filling critical gaps in manufacturing cell and gene therapy — revolutionary yet complex treatments with the potential to change medicine — is no easy feat. It’s a given that it takes years of planning, millions in financial resources, a focused business model and ample technical and regulatory expertise.
Comments